Tag Archive for: Tepezza

With the settlement of a big acquisition behind them and a strong portfolio of therapeutics that continues to expand, hopes for smooth sailing are on the horizon.

Amgen said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.

The U.S. Federal Trade Commission on Friday reached a settlement with Amgen Inc. allowing the drugmaker to go ahead with its $27.8 billion acquisition of Horizon Therapeutics, dropping its earlier objections to the deal.

The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc.’s $27.8 billion deal to buy Horizon Therapeutics PLC (HZNP.O), a person familiar with the matter told Reuters.

Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.

And then there were two. Janssen (Johnson & Johnson) is no longer in the running to acquire rare disease player Horizon Therapeutics, the company announced Saturday. 

The Ireland-based company issued a statement confirming that it is engaged in “highly preliminary discussions” with Amgen, Janssen, and Sanofi. Any acquisition of Horizon Therapeutics would be among the biggest deals of 2022.

The top pharmaceutical companies and brands in this year’s Outcomes Creativity Index elevated their messaging by breaking down barriers, debunking myths and giving patients a stronger voice.

The top performers among drugs launched in 2020 were each the first of their kind.